Telik (TELK) Resumes Trading, Up 73%
Telik Inc. (NASDAQ: TELK) has resumed trading following the volatility trading halt and is now up 73% to $2.51. The company was granted orphan drug status for Telintra for myelodysplastic syndrome.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Shire plc (SHPG) Said Considering Bid for NPS Pharma (NPSP)
- Wall Street Looks to Profit from New and Improved Cuba Relations (CUBA) (RCL) (CCL)
- The Pantry, Inc. (PTRY) halted with news pending